Botulinum toxin type-A effect as a preemptive treatment in a model of acute trigeminal pain: A pre-clinical double-blind and placebo-controlled study;Toxina botulínica do tipo-A no tratamento preemptivo da dor trigeminal aguda: Estudo pré-clínico duplo cego placebo controlado

Arquivos de Neuro-Psiquiatria

Volumn 69, Issue 1, 2011, Pages 56-63

  Piovesan, Elcio Juliato ^a,b   da Silva Leite, Lucas ^a,b   Teive, Helio Ghizoni ^a   Kowacs, Pedro André ^a   Mulinari, Rogério Andrade ^a,b   Radunz, Victor ^a,b   Utiumi, Marco ^a,b   Campos, Helder Groenwold ^a,b   Werneck, Lineu Cesar ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Experimental Neurology Lab   (Brazil)

Author keywords

Antinociceptive effect; Botulinum neurotoxin type A; Orofacial pain; Preemptive treatment

Indexed keywords

BOTULINUM TOXIN A;

ANTINOCICEPTION; ARTICLE; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; INFLAMMATION; MALE; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD BEHAVIOR; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TRIGEMINUS NEURALGIA;

EID: 79952332075     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2011000100012     Document Type: Article

References (24)

1. Weiskopf RB. Clinical concepts and commentary. Anesthesiology 2000;93: 1138-1143.
2. Woolf CJ, Chong MS. Preemptive analgesia: treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993; 77:362-379.
3. Aida S. The challenge of preemptive analgesia. Pain 2005;13:1-4.
4. Hou YP, Zhang YP, Song YF, Zhu CM, Wang YC, Xie GL. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol 2007;85:209-214.
5. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their antinociceptive potential. J Cell Sci 2007;120:2864-2874.
6. Höltje M, Hofmann F, Lux R, Veh RW, Just I, Ahnert-Hilger G. Glutamate uptake and release by astrocytes are enhanced by Clostridium botulinum C3 protein. J Biol Chem 2008;283:9289-9299.
7. Tugnoli V, Capone JG, Eleopra R, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007;130:76-83.
8. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-188.
9. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001;24:487-517.
10. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68.
11. Amaya F, Oh-hashi K, Naruse Y, et al. Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. Brain Res 2003;963:190-196.
12. Wang S, Redgrave P. Microinjections of muscimol into lateral superior colliculus disrupt orienting and oral movements in the formalin model of pain. Neuroscience 1997;81:967-988.
13. Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res Rev 2004;46:295-309.
14. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004;19(Suppl 8):S92-S100.
15. Luvisetto S, Marinelli S, Lucchetti F, et al. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res 2006;1082: 124-131.
16. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. NeuroToxicol 2005;26:785-793.
17. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-133.
18. Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005;65:1306-1308.
19. Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024- 026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006;7:688-696.
20. Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007;27:492-503.
21. Farinelli I, Coloprisco G, De Filippis S, Martelletti P. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 2006;7:407-412.
22. Freitag FG. Botulinum toxin type A in chronic migraine. Expert Rev Neurother 2007;7:463-470.
23. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64:274-283.
24. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009;72:1473-1478.